A new Paradigm in the Development and Manufacturing of Antibody-drug Conjugates

from The Onco'Zine Brief with Peter Hofland · host Peter Hofland

Recorded during CPhI World Wide, October 24 - 27, 2017 in Frankfurt Germany, Peter Hofland and Sonia Portillo interview Charlie Johnson, the CEO of ADC Bio. ADC Bio, a biotechnology company developing new process technology to speed, simplify and significantly lower the production costs of the latest generation of novel anti-cancer blockbuster drugs known as Antibody-drug Conjugates or ADCs.

Episode metadata supplied by the publisher feed · Published Dec 16, 2017

Embed this episode

Attribution link and audio player

NOW PLAYING

A new Paradigm in the Development and Manufacturing of Antibody-drug Conjugates

0:00 26:41

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of The Onco'Zine Brief with Peter Hofland?

This episode is 26 minutes long.

When was this The Onco'Zine Brief with Peter Hofland episode published?

This episode was published on December 16, 2017.

Can I download this The Onco'Zine Brief with Peter Hofland episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!